ORPHA:238763
Glaucoma secondary to spherophakia/ectopia lentis and megalocornea
Also known as: Megalocornea-spherophakia-secondary glaucoma syndrome
Publications
1
8th percentile
Trials
0
Interventional, condition-specific
Researchers
5
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Glaucoma secondary to spherophakia/ectopia lentis and megalocornea is a rare, genetic, non-syndromic developmental defect of the eye disorder characterized by megalocornea associated with spherophakia and/or ectopia lentis leading to pupillary block and secondary glaucoma. Additional features may include flat irides, iridodonesis, axial myopia, very deep anterior chambers, miotic, oval pupils without well-defined borders, ocular pain and irritability manifesting as conjunctival injection, corneal edema and central scarring, as well as a high arched palate.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016559
- UMLS:C5190883
Additional Mondo synonyms (1)
megalocornea-spherophakia-secondary glaucoma syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1 matched papers (1 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 1627 for broader category glaucoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1
1 paper have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1 in the last 10 years · high confidence · 8th percentile (publications denominator)
Phrase hits: 1 · MeSH hits: 0
Who's working on it?
5
Distinct author names in 1 sampled paper — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Ali MJ1 paper · 2017
Ophthalmic Plastic Surgery, L V Prasad Eye Institute, Hyderabad, India.
Papers in Europe PMC - 02Augusteyn RC1 paper · 2017
School of Optometry and Vision Science, The University of New South Wales, Kensington, New South Wales, Australia.
Papers in Europe PMC - 03Mohamed A1 paper · 2017
School of Optometry and Vision Science, The University of New South Wales, Kensington, New South Wales, Australia.
Papers in Europe PMC - 04Parel JA1 paper · 2017
Vision Cooperative Research Centre, Brien Holden Vision Institute, Kensington, New South Wales, Australia.
Papers in Europe PMC - 05Sangwan VS1 paper · 2017
Ophthalmic Biophysics Laboratory, L V Prasad Eye Institute, Hyderabad, India.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 1,627 trials are registered for glaucoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 26 October 2026 · last trial check 26 October 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5498 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
1,627 interventional trials matched glaucoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: glaucoma
1,627
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07015034·RECRUITING·Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice
Conditions: Vision Impairment and Blindness · Glaucoma · Age-Related Macular Degeneration · Cataract·Matched via name phrase
- NCT07075718·RECRUITING·Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Conditions: Glaucoma·Matched via name phrase
- NCT04957329·RECRUITING·Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells
Conditions: Glaucoma · Ocular Hypertension·Matched via name phrase
- NCT05344274·RECRUITING·Retinal Blood Flow and Autoregulation
Conditions: Glaucoma·Matched via name phrase
- NCT07803536·NOT YET RECRUITING·Effect of Late Ripcord Removal From Glaucoma Drainage Device
Conditions: GLAUCOMA 1, OPEN ANGLE, D (Disorder) · Glaucoma·Matched via name phrase
- NCT06854198·RECRUITING·Glaucoma Screening to Enhance At-Risk Californians' Health
Conditions: Glaucoma·Matched via name phrase
- NCT07488234·NOT YET RECRUITING·Impact of a Glaucoma Awareness Program on Treatment Adherence
Conditions: Glaucoma·Matched via name phrase
- NCT06731582·ENROLLING BY INVITATION·Nicotinamide Supplementation in Glaucoma
Conditions: Glaucoma·Matched via name phrase
- NCT06680245·NOT YET RECRUITING·Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery
Conditions: Glaucoma·Matched via name phrase
- NCT06865235·RECRUITING·Efficacy and Safety of Gonioscopy Assisted Transluminal Trabeculotomy in Patients with Primary Open-angle Glaucoma and Cataract.
Conditions: Open Angle Glaucoma (OAG)·Matched via name phrase
- NCT07228221·RECRUITING·Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
Conditions: Open Angle Glaucoma · Pigmentary Glaucoma · Pseudoexfoliation Glaucoma·Matched via name phrase
- NCT04401982·RECRUITING·Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Conditions: Ocular Hypertension · Suspect Glaucoma·Matched via name phrase
- NCT07847073·RECRUITING·Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Conditions: Open Angle Glaucoma (OAG) · Glaucoma·Matched via name phrase
- NCT05696561·RECRUITING·Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle Glaucoma
Conditions: OAG - Open-Angle Glaucoma·Matched via name phrase
- NCT07777861·RECRUITING·A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
Conditions: Primary Open-Angle Glaucoma · Optic Nerve Injury·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Glaucoma secondary to spherophakia/ectopia lentis and megalocornea — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Glaucoma secondary to spherophakia/ectopia lentis and megalocornea" OR "Megalocornea-spherophakia-secondary glaucoma syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Glaucoma secondary to spherophakia/ectopia lentis and megalocornea" OR "Megalocornea-spherophakia-secondary glaucoma syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"glaucoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T10:26:50.212Z
